Mylan Pharmaceuticals Voluntarily Recalls Insulin Glargine Injection Pens

Early in July, Mylan Pharmaceuticals, Inc. voluntarily recalled a batch of its prefilled Insulin Glargine Injection pens that come in 100 units/mL, 3 mL. The pens include an insulin analog that is long-acting. Doctors prescribe it for glycemic controls in both adults and children who have type 1 or type diabetes. If you were injured or a loved one was lost due to uncontrolled blood sugar while using Insulin Glargine Injection pens or another type of insulin injection pen, you should call the experienced Chicago-based product liability lawsuits of Moll Law Group to see whether you have a viable claim. Billions have been recovered in lawsuits with which we’ve been involved.

Call Moll Law Group About Your Insulin Injection Pen Claim

The pens in questions are packed five pens to a carton and sold to patients with diabetes. The carton includes information about the product, batch number, and the date the pens expire. The manufacturer recalled a batch that omitted a label on certain pens. Due to this lack of labeling, a patient could mix up the products and strengths of the unbranded pens. This, in turn, could lead to insufficient glycemic control, and either excessively high or low blood sugar.

Biocon Sdn. Bhd made the affected pens, which are not branded and are interchangeable with biosimilar Insulin Glargine-yfgn pens. They affected pens were distributed by Mylan Specialty L.P in the United States between April 4 – May 5, 2022. The branded Semglee injection pen is not affected. While no adverse events have been reported so far, serious harm could be experienced by a patient who needs to control his or her insulin.

Viatris commenced the recall by notifying distributors and retailers and made the FDA aware of the recall. The manufacturer also arranged for the recalled pens to be returned. Wholesalers are expected to look at their inventory and stop distributing the batch. Retailers are also expected to stop distributing pens from the recalled batch. If you are a consumer with a pen that is not labeled you should contact the manufacturer so that you can get information about how to return it. You can call Viatris Customer Relations by phone at 1-800-796-9526 or email the company’s customer service email.

But what if you or a loved one has already been harmed by the unlabeled pen? You should immediately seek medical care from your doctor or other provider and report the adverse event.

Our lawyers may be able to recover compensation for any injuries or losses you experienced as a result of the pen that was not labeled. Generally, product liability lawsuits may be brought in connection with products that are defective in terms of their marketing, manufacturing or design. Marketing defects often involve failure to warn, but they can also include a lack of instructions or information needed to safely use the product. In this case, since there is a problem with the labeling, we would likely need to consult an expert on marketing defects.

Call Our Product Liability Attorneys

If you were injured or lost a loved one because your Insulin Glargine Injection pen or other insulin injection pen was not labeled, and therefore sugars were not controlled as needed, you should call the seasoned lawyers of Moll Law Group about whether you have grounds to bring a lawsuit. We represent injured plaintiffs across the country. Billions have been recovered in product liability lawsuits with which we’ve been involved. Please complete our online form or contact us at 312.462.1700.